Holen Sie sich die Stockscreener-App
27.00
1.83%
0.28
Schlusskurs vom Vortag:
$26.72
Offen:
$26.78
24-Stunden-Volumen:
190.52K
Relative Volume:
1.32
Marktkapitalisierung:
$1.57B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.28M
KGV:
-13.53
EPS:
-1.9957
Netto-Cashflow:
$-57.45M
1W Leistung:
+7.89%
1M Leistung:
+32.86%
6M Leistung:
+50.41%
1J Leistung:
+20.24%
1-Tages-Spanne:
$26.33
$27.43
1-Wochen-Bereich:
$24.16
$27.43
52-Wochen-Spanne:
$14.00
$27.43
Oculis Holding Ag Stock (OCS) Company Profile
Firmenname
Oculis Holding Ag
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie OCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
27.11 | 1.54B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-19 | Eingeleitet | JP Morgan | Overweight |
| 2025-08-27 | Eingeleitet | Needham | Buy |
| 2023-12-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-10-05 | Eingeleitet | Stifel | Buy |
| 2023-06-14 | Eingeleitet | BofA Securities | Buy |
| 2023-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-06-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-05-10 | Eingeleitet | Pareto | Buy |
| 2023-04-28 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Oculis Holding Ag Aktie (OCS) Neueste Nachrichten
Oculis (NASDAQ:OCS) Hits New 12-Month HighShould You Buy? - MarketBeat
Market Fear: Is Oculis Holding AG Equity Warrant forming higher highs and higher lows2025 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Portfolio Update: Will IPGP outperform tech stocksTrade Risk Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Update Report: Can Oculis Holding AG continue delivering strong returnsDay Trade & Safe Capital Allocation Plans - baoquankhu1.vn
Is Oculis Holding AG Equity Warrant stock positioned for digital transformation2025 Earnings Impact & Free High Return Stock Watch Alerts - bollywoodhelpline.com
Oculis (NASDAQ:OCS) Reaches New 1-Year HighHere's Why - MarketBeat
Trading Systems Reacting to (OCS) Volatility - Stock Traders Daily
Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation - Sahm
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major milestones in 2024–2027 - TradingView — Track All Markets
US Market Wrap: How does Oculis Holding AG compare to its peersJuly 2025 News Drivers & Community Consensus Stock Picks - baoquankhu1.vn
Forecast Cut: How does Hubbell Incorporated correlate with NasdaqInflation Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Brokerages Set Oculis Holding AG (NASDAQ:OCS) Target Price at $41.50 - Defense World
Oculis Holding AG (NASDAQ:OCS) Sees Significant Growth in Short Interest - MarketBeat
Market Outlook: Is Oculis Holding AG Equity Warrant a top pick in the sectorWeekly Gains Report & Technical Confirmation Trade Alerts - baoquankhu1.vn
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - Yahoo Finance
Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis - simplywall.st
Why Oculis Holding AG stock could benefit from AI revolutionWeekly Trade Recap & Technical Pattern Based Signals - Улправда
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy - MSN
Is Oculis Holding AG stock recession proofEarnings Growth Report & Smart Money Movement Alerts - Улправда
Oculis (NASDAQ:OCS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis - Indian Pharma Post
Why Oculis Holding AG Equity Warrant stock could rally in 2025 - Улправда
Can Oculis Holding AG Equity Warrant stock beat analyst upgradesJuly 2025 Spike Watch & Reliable Breakout Forecasts - Улправда
Will Oculis Holding AG stock maintain momentum in 2025Trade Exit Report & Expert Curated Trade Ideas - Улправда
IPO Launch: Why Oculis Holding AG stock is recommended by analystsWeekly Profit Report & Free Reliable Trade Execution Plans - Улправда
Can Oculis Holding AG (CR5) stock surprise with quarterly resultsMarket Movement Recap & Long-Term Capital Growth Ideas - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock attracts global investorsCandlestick Trading Patterns & Low Risk Trading Plans - bollywoodhelpline.com
Weekly Earnings: Can Oculis Holding AG Equity Warrant stock beat analyst upgradesQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Will Oculis Holding AG Equity Warrant stock deliver consistent dividendsJuly 2025 Update & Long-Term Safe Investment Ideas - Улправда
Why Oculis Holding AG stock is recommended by analysts2025 Price Momentum & Low Risk High Reward Ideas - Улправда
OCSOculis Holding Latest Stock News & Market Updates - Stock Titan
Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline - marketscreener.com
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyFibonacci Retracement Levels & Unlock Smart Investment Tactics That Work - Улправда
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference - The Manila Times
Oculis Holding AG Advances PIONEER Program with Breakthrough Therapy Designation for Privosegtor and Prepares for Upcoming J.P. Morgan Healthcare Conference Presentation - Quiver Quantitative
Oculis to Showcase Transformative Late-stage Pipeline in - GlobeNewswire
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis - Eyes On Eyecare
Should I hold or sell Oculis Holding AG Equity Warrant stock in 20252026 world cup usa national team qualification goalkeepers transition play odds analysis insights - ulpravda.ru
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2026 world cup usa national team qualification star players transition play knockout prediction guide - Улправда
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
FDA grants breakthrough therapy designation to Oculis’ privosegtor for optic neuritis - Ophthalmology Times
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
Oculis stock surges after FDA grants breakthrough therapy designation - Investing.com India
Aug Rallies: Can Oculis Holding AG CR5 stock surprise with quarterly resultsEarnings Beat & Reliable Breakout Forecasts - Bộ Nội Vụ
Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - marketscreener.com
Oculis Holding Says FDA Granted Breakthrough Therapy Designation for Privosegtor - marketscreener.com
Why Oculis Is Rising In Pre-market? - Nasdaq
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - The Manila Times
Finanzdaten der Oculis Holding Ag-Aktie (OCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):